GENE ONLINE|News &
Opinion
Blog

2023-08-16|

Gilead Reaches $247M Settlement in Antitrust Lawsuit

by GeneOnline
Share To

In a significant development, KPH Healthcare Services, Inc., commonly known as Kinney Drugs, Inc., has successfully reached a settlement in an ongoing legal battle against pharmaceutical giant Gilead Sciences, Inc. The lawsuit, filed under the title “In Re: HIV Antitrust Litigation,” accused Gilead of engaging in anticompetitive practices related to its HIV drugs. The settlement, amounting to an impressive $246.75 million, is poised to benefit direct-payor plaintiffs (DPPs) and marks a pivotal moment in the fight against monopolistic tactics within the pharmaceutical industry.

Related articles: Gilead Launches Global All4liver Grant Program To Help Achieve The World Health Organization’s Goal of viral Hepatitis Elimination by 2030 

Allegations of Anticompetitive Behavior

At the core of the lawsuit were allegations that Gilead employed tactics to stifle competition and maintain its dominance in the market. The company purportedly resorted to “pay-for-delay” strategies, whereby Gilead sought to hinder the entrance of generic alternatives to its HIV drugs. This alleged behavior particularly targeted patients whose previous drugs had generic alternatives available. The plaintiffs contended that Gilead utilized these tactics to shift HIV patients from the older drugs to its newer offerings, thereby maintaining its hold on the market and obstructing fair competition.

A Landmark Settlement

The settlement agreement, now pending preliminary court approval, represents a substantial step toward holding pharmaceutical giants accountable for their actions. Under the terms of the settlement, Gilead will pay a staggering $246.75 million to the direct-payor plaintiffs. Additionally, the settlement fund will cover all administrative expenses, court-approved attorney fees, costs, and a service award for the representative plaintiff. After these allocations, any remaining funds will be distributed pro rata to class members who can provide a valid claim based on their purchase of specific drugs, including Truvada, Atripla, and their generic equivalents. A hearing to review and approve the settlement is scheduled for September 21, 2023.

Antitrust Allegations and Their Complexity

The litigation originated in 2020 and revolved around claims brought forth by both indirect purchasers and direct purchasers of certain combination antiretroviral therapy (cART) drugs designed to combat HIV. The drugs in question were produced or sold by Gilead, along with BMS and Janssen. The lawsuit included a spectrum of claims, primarily revolving around Gilead’s alleged manipulation of the market through various tactics.

These claims encompassed:

  • TAF Claims: Accusations that Gilead delayed the launch of its new drug, TAF, until the introduction of a generic alternative of its older drug, TDF, was imminent. Gilead was purportedly involved in tactics to compel HIV patients to switch from TDF drugs to TAF drugs.
  • NGR Claims: The lawsuit also centered around collaboration agreements between Gilead and BMS, which allegedly contained provisions restraining generic competition. These No-Generic Restraint (NGR) clauses reportedly hindered collaboration partners from creating competing products.
  • MFE/MFEP Claims: The third category of claims related to an alleged settlement agreement between Gilead and Teva. It was claimed that Gilead agreed to delay Teva’s entry into the market, in exchange for Teva receiving preferential treatment in terms of market entry.

The Path Forward

This settlement stands as a significant moment in the ongoing effort to ensure fair competition within the pharmaceutical sector. The court’s recognition of the complexities involved in antitrust litigation and its recent ruling on summary judgment motions showcase the evolving landscape of legal battles against industry giants. As the court proceeds to review and approve the settlement, the outcome could potentially set a precedent for addressing similar anticompetitive behaviors in the future.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Is Trump Halting Research? Harvard Sues Over Unlawful Funding Freeze and Government Overreach
2025-04-21
Novo Nordisk Takes on Eli Lilly in Weight Loss Drug Battle with Wegovy Price Cut
2025-03-06
Eli Lilly Steals the Spotlight at JPM 2025 with $2.5 Billion Power Move Acquisition
2025-01-16
LATEST
Lupin Secures US FDA Tentative Approval for Oxcarbazepine ER Tablets Manufactured in Nagpur
2025-06-18
Investor Trust and Market Timing Shape the New IPO Playbook
2025-06-18
Global Pharmaceutical Sector Records $6.96 Billion in May 2025 Deal Activity with Three Major Agreements Driving 59 Percent of M&A Value
2025-06-18
Eli Lilly Acquires SiteOne Therapeutics to Develop Non-Opioid Pain Treatment STC-004
2025-06-18
New Device Promises to Streamline CAR T-Cell Therapy Production for Earlier Cancer Treatment
2025-06-18
Roche Reports Near-Complete Suppression of Disability Progression in RMS Patients Over Two Years with BTK Inhibitor
2025-06-18
Technological Advancements Reduce R&D Costs and Propel Growth of Cell and Gene Therapies in Biopharmaceutical Sector
2025-06-18
EVENT
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top